Brenda Banwell

Add links
From Wikipedia, the free encyclopedia
Brenda Banwell
Born1967
Winnipeg, Canada
Alma materUniversity of Western Ontario
Known forInternational expert in pediatric demyelinating diseases including multiple sclerosis, neuromyelitis optica and MOG antibody disease
Awards2007 Women Against Multiple Sclerosis - Woman of the Year Award, 2015 American Academy of Neurology Sydney Carter Lifetime Achievement Award in Child Neurology, 2016 The Lady Barbara Colyton Prize for Autoimmune Research, Perelman School of Medicine, University of Pennsylvania
Scientific career
FieldsNeurology, pediatrics, neuroimmunology, neuromuscular disease
InstitutionsUniversity of Toronto
University of Pennsylvania Medical School
Children's Hospital of Philadelphia

Brenda Banwell is Chief of the Division of Neurology and Co-Director of the Neuroscience Center, and Professor of Neurology at Children's Hospital of Philadelphia and holder of the Grace R. Loeb Endowed Chair in Neurosciences. She also holds the title of Professor of Pediatrics and Neurology at the Perelman School of Medicine at the University of Pennsylvania.

Banwell is the co-director of the Pediatric Multiple Sclerosis and Neuroinflammatory Disorders Clinic at the Children's Hospital of Philadelphia. She has published extensively on pediatric demyelinating diseases including multiple sclerosis, neuromyelitis optica and MOG antibody disease. Banwell is the co-director of the Canadian Pediatric Demyelinating Disease Network,[1] the chair of the International Pediatric Multiple Sclerosis Study Group,[2] and the chair of the International Medical and Scientific Board of the MS International Federation.[3] Banwell also sits on the International Advisory Committee on Clinical Trials of New Drugs in Multiple Sclerosis.[4]

Banwell is a fellow of the American Academy of Neurology,[5] and serves as vice chair of the Academic Neurology Committee.[6] She has been active in the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), delivering the 2022 ECTRIMS lecture.[7]

Early life and education[edit]

Banwell was born in Winnipeg, Canada.[8] She did her undergraduate training at the University of Western Ontario, where she remained for her MD and her residency in pediatrics. She completed her pediatric neurology residency at the University of Toronto Hospital for Sick Children, where she was chief resident. She then went to Mayo Clinic for a two year fellowship in neuromuscular disease.[9]

Career and Research[edit]

Banwell returned to the University of Toronto Hospital for Sick Children as an assistant professor in 1999. She became a full professor at the University of Toronto in 2012. In July 2012, she took a position as full professor in neurology and pediatrics at and chief of neurology at the Children's Hospital of Philadelphia.[10]

Research in Multiple Sclerosis[edit]

Banwell initially took her position at the University of Toronto intending to focus on neuromuscular disease in children. When she inherited five patients with multiple sclerosis from a retiring physician, she reports that her focus shifted to pediatric demyelinating disease.[11]

To better study a rare disease, Banwell created the Canadian Pediatric Demyelinating Disease Network in 2004, a multi-site network including all pediatric health-care facilities in Canada.[12] This has allowed Banwell and co-investigators to better understand diagnosis, treatment, and comorbidities of pediatric demyelinating disease.

Diagnosis: Banwell has been instrumented in evaluating the use of the McDonald criteria - standardized criteria to diagnose multiple sclerosis through determination of dissemination of central nervous system demyelination in space and time - in pediatric multiple sclerosis.[13] She has been the primary pediatric neurologist involved in international work to develop updates of the McDonald criteria for adults and children in 2010[14] and in 2017.[15]

Treatment: While many medications have become available for the treatment of multiple sclerosis over the last three decades, testing in children has been challenging due to the rarity of pediatric multiple sclerosis and ethical considerations with the use of placebo.[16] To facilitate and improve clinical trial design, Banwell created and currently chairs the International Pediatric Multiple Sclerosis Study Group. This allowed for the success of the PARADIGMS clinical trial, studying the safety and efficacy of fingolimod in a comparison with interferon beta-1a,[17] and led to approval of fingolimod by the Food and Drug Administration for pediatric multiple sclerosis, the first approval of a medication for this indication.[18]

Comorbidities: Banwell's work has shown that while children may recover physically from flares of multiple sclerosis, neuropsychological deficits may be apparent on testing, particularly in those who present at a younger age.[19][20] This knowledge has changed how families are counseled and supported through the diagnosis of multiple sclerosis.[21]

Acute Disseminated Encephalomyelitis, Neuromyelitis Optica and MOG Antibody Disease[edit]

Because demyelinating diseases in the pediatric population can be difficult to distinguish from each other, Banwell has worked to define and provide clinical guidelines for physicians working to delineate the diseases.[22]

In 2015, Banwell was on the International Panel for NMO Diagnosis (IPND) to develop international consensus diagnostic criteria for what became termed neuromyelitis optica spectrum disorder (NMO-SD).[23] She has also worked to determine the best treatment options for pediatric NMO-SD.

MOG antibody disease (MOGAD) was first described in the early 2000s as a subset of cases of neuromyelitis optica with antibodies to myelin oligocyte glycoprotein (MOG).[24] Banwell and colleagues worked to characterize pediatric MOGAD to determine methods of diagnosis,[25] treatment options,[26] and prognosis.[27]

Awards and honors[edit]

References[edit]

  1. ^ "Canadian Pediatric Demyelinating Disease Network". Maelstrom.
  2. ^ "INTERNATIONAL PEDIATRIC MULTIPLE SCLEROSIS STUDY GROUP (IPMSSG) FOR MEDICAL PROFESSIONALS". International Pediatric Multiple Sclerosis Study Group. 31 October 2014. Retrieved 30 December 2023.
  3. ^ "International Medical and Scientific Board". MS International Federation. Retrieved 30 December 2023.
  4. ^ "Dr. Brenda Banwell". MS Canada.
  5. ^ "The American Academy of Neurology for Pediatric Neurologists". SAGE Neuroscience and Neurology.
  6. ^ "Academic Neurology Committee". American Academy of Neurology.
  7. ^ Banwell, Brenda. "European Committee for Treatment and Research in Multiple Sclerosis". Multiple Sclerosis Journal. 29 (7). doi:10.1177/13524585231171047. S2CID 258968920.
  8. ^ Ashwal, Stephen (2021). Child Neurology: Its Origins, Founders, Growth and Evolution. New York: Elsevier Science. p. 609. ISBN 978-0128216354.
  9. ^ "02/09/2018 Brenda Louise Banwell, MD Addres" (PDF). eCTRIMS 2021. Retrieved 30 December 2023.
  10. ^ "Medical Advisory Board: Brenda L. Banwell, MD". MS Cure Fund. Retrieved 30 December 2023.
  11. ^ "Dr. Brenda Banwell". Main Line Today. 26 Sep 2014. Retrieved 30 December 2023.
  12. ^ "MS Scientific Research Foundation funded study boosts efforts in pediatric MS research, implications for understanding adult-onset MS". MS Canada. 21 September 2023. Retrieved 30 December 2023.
  13. ^ Hahn, CD; Shroff, MM; Blaser, SI; Banwell, BL (Mar 2004). "MRI criteria for multiple sclerosis: Evaluation in a pediatric cohort". Neurology. 62 (5): 806–808. doi:10.1212/01.wnl.0000113723.36715.a6. PMID 15007138. S2CID 793225.
  14. ^ Polman, CH; Reingold, SC; Banwell, B; Waubant, E; Weinshenker, B; Wolinsky, JS (Feb 2011). "Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria". Annals of Neurology. 69 (2): 292–302. doi:10.1002/ana.22366. PMC 3084507. PMID 21387374.
  15. ^ Thompson, AJ; Banwell, BL; Barkhof, F; Carroll, G; Coetzee, T; Comi, G (21 Dec 2017). "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria". The Lancet. 17 (2): 162–173. doi:10.1016/S1474-4422(17)30470-2. PMID 29275977. S2CID 206164600.
  16. ^ Waubant, E; Banwell, B; Wassmer, E; Sormani, M; Amato, M; Hintzen, R; Krupp, L; Rostasy, K; Tenembaum, S; Chitnis, T (May 28, 2019). "Clinical trials of disease-modifying agents in pediatric MS". Neurology. 92 (22). doi:10.1212/WNL.0000000000007572. PMC 6556085.
  17. ^ Chitnis, T; Arnold, DL; Banwell, BL; Brück, W; Ghezzi, A; Wolinsky, J (September 13, 2018). "Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis". The New England Journal of Medicine. 379 (11): 1017–1027. doi:10.1056/NEJMoa1800149. PMID 30207920.
  18. ^ "FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients". FDA News Release. U.S. Food and Drug Administration. 11 May 2018. Retrieved 30 December 2023.
  19. ^ Banwell, B; Anderson, PE (Mar 2005). "The cognitive burden of multiple sclerosis in children". Neurology. 64 (5): 891–4. doi:10.1212/01.WNL.0000152896.35341.51. PMID 15753431. S2CID 6532050.
  20. ^ Ness, JM; Chabas, D; Sadovnick, AD; Pohl, D; Banwell, B; Weinstock-Guttman, B; International Pediatric MS Study Group (Apr 2007). "Clinical features of children and adolescents with multiple sclerosis". Neurology. 68 (16_suppl_2). doi:10.1212/01.wnl.0000259447.77476.a9. PMID 17438237. S2CID 23680547.
  21. ^ Akbar, N; Till, C; Banwell, B (2018). "Pediatric multiple sclerosis and cognition". American Psychological Association.: 223–244. doi:10.1037/0000097-012. ISBN 978-1-4338-2932-1.
  22. ^ Dale, RC; Brilot, F; Banwell, B (2009). "Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis". Curr Opin Neurol . 22 (3): 233–240. doi:10.1097/wco.0b013e32832b4c47. S2CID 36302147.
  23. ^ Wingerchuk, DM; Banwell, B; Bennett, JL; Cabre, P; Carroll, W; Chitnis, T (2015). "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders". Neurology. 85 (2): 177–189. doi:10.1212/WNL.0000000000001729. PMC 4515040.
  24. ^ Haase, CG; Schmidt, S (2001). "Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica". Neuroscience Letters. 307 (2): 131–133. doi:10.1016/s0304-3940(01)01949-8. PMID 11427318. S2CID 21184790.
  25. ^ Waters, P; Fadda, G; Woodhall, M; O'Mahony, J; Brown, RA; Castro, DA; Banwell, Brenda; Bar-Or, Amit; Canadian Pediatric Demyelinating Disease Network (Jan 2020). "Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes". JAMA Neurol . 77 (1): 82–93. doi:10.1001/jamaneurol.2019.2940. PMC 6763982. PMID 31545352.
  26. ^ Hacohen, Y; Banwell, B (2019). "Treatment Approaches for MOG-Ab-Associated Demyelination in Children". Curr Treat Options Neurol. 21 (1). doi:10.1007/s11940-019-0541-x. PMC 6342853.
  27. ^ Tenembaum, S; Yeh, E; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC) (Jun 2020). "Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis". Front Pediatr. 8. doi:10.3389/fped.2020.00339. PMC 7330096. PMID 32671002.
  28. ^ "Brenda Banwell". Children's Hospital of Philadelphia. 24 August 2014.
  29. ^ Banwell, Brenda (2016). "Pediatric multiple sclerosis The 2015 Sydney Carter Award Lecture". Neurology. 87 (8): 822–826. doi:10.1212/WNL.0000000000003014. PMID 27550891.
  30. ^ "Penn Medicine Awards of Excellence: 2016 Recipients". Perelman School of Medicine. Retrieved 31 December 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Brenda_Banwell&oldid=1209806547"